Lori Lawley
Finanzdirektor/CFO bei LUMOS PHARMA, INC.
Vermögen: 34 536 $ am 30.04.2024
Aktive Positionen von Lori Lawley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LUMOS PHARMA, INC. | Unternehmenssekretär | 01.03.2020 | - |
Finanzdirektor/CFO | 04.07.2021 | - | |
Comptroller/Controller/Auditor | 01.03.2020 | - |
Karriereverlauf von Lori Lawley
Ehemalige bekannte Positionen von Lori Lawley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LUMOS PHARMA, INC. | Comptroller/Controller/Auditor | 26.07.2018 | 01.03.2020 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.10.2014 | 01.04.2015 |
Ausbildung von Lori Lawley
McCombs School of Business | Graduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
2 |
Operativ
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Corporate Secretary | 1 |
Sektoral
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
LUMOS PHARMA, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
NewLink Genetics Corp.
NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
- Börse
- Insiders
- Lori Lawley
- Erfahrung